AbbVie delivered a total return that contributed to the strong start for Dividend Kings in January 2026, as the group rose 4.66% through January 23rd versus the S&P 500’s 1.07% gain. In 2025 the Dividend Kings underperformed the broad market, averaging a 4.91% total return versus the SPY’s 17.72%, yet 14 members still outpaced the index. Nineteen Kings, including AbbVie, currently screen as potentially undervalued and offer long-term annualized expected returns of at least 10%, based on discounted cash flow analyses and consensus dividend growth forecasts.

In its most recent 13F filing, Commerzbank Aktiengesellschaft FI reduced its AbbVie stake by 30.5%, selling 39,586 shares and ending the period with 90,102 shares valued at approximately $20.9 million. Other large moves include Norges Bank’s new stake worth roughly $4.29 billion and Vanguard Group’s incremental increase of 3.38 million shares during the second quarter. Analyst activity has been active: two firms maintain Strong Buy opinions, thirteen rate the shares as Buy and eight as Hold. UBS reissued a Neutral view in mid-January, while BMO Capital Markets reaffirmed an Outperform rating later that week, reflecting mixed but generally constructive sentiment.

On October 31st AbbVie reported third-quarter adjusted EPS of $1.86, beating the $1.77 consensus by $0.09, while revenue rose 9.1% year-over-year to $15.78 billion versus forecasts of $15.58 billion. The company achieved a return on equity of 3,216.47% and a net margin of 4.00%. Management set Q4 2025 EPS guidance at a midpoint of $3.34 and analysts project full-year EPS of 12.31. AbbVie’s board also approved a quarterly dividend of $1.73 per share, up from $1.64, representing an annualized payout of $6.92 and a payout ratio of 524.24%, payable February 17th to shareholders of record January 16th.